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Abstract. Receptor for advanced glycation end-products 
(RAGE) is a pattern recognition receptor implicated in the 
pathogenesis of certain types of cancer. In the present study, 
papaverine was identified as a RAGE inhibitor using the 
conversion to small molecules through optimized-peptide 
strategy drug design system. Papaverine significantly inhib-
ited RAGE-dependent nuclear factor κ-B activation driven by 
high mobility group box-1, a RAGE ligand. Using RAGE- or 
dominant‑negative RAGE‑expressing HT1080 human fibro-
sarcoma cells, the present study revealed that papaverine 
suppressed RAGE-dependent cell proliferation and migra-
tion dose‑dependently. Furthermore, papaverine significantly 
inhibited cell invasion. The results of the present study 
suggested that papaverine could inhibit RAGE, and provided 
novel insights into the field of RAGE biology, particularly 
anticancer therapies.
Introduction
Receptor for advanced glycation end products (RAGE) is 
a pattern recognition receptor that binds multiple ligands, 
including AGE (1), S100 proteins (2), lipopolysaccharides (3), 
phosphatidylserine (4), amyloid-β (Aβ) (5), and high mobility 
group box (HMGB)-1 (6). Interactions of these diverse ligands 
with RAGE result in intracellular signaling, including nuclear 
factor κ-B (NF-κB) activation, which results in pathogenic 
processes such as diabetic complications (7), inflamma-
tory diseases, Alzheimer's disease (AD) (8) and cancer (9). 
Takeuchi et al (10) demonstrated that RAGE expression 
in HT1080 human fibrosarcoma cells induced tumor cells 
to proliferate, migrate, invade and metastasize. HMGB-1 
was revealed to induce RAS-related C3 botulinum toxin 
substrate (Rac)1 and cell division control protein 42 homolog 
(Cdc42) functions in RAGE‑expressing HT1080 fibrosarcoma 
cells (10). Epidemiological studies also demonstrated that 
RAGE expression was associated with tumor malignancies 
of the stomach (11), colon and rectum (12-14), prostate (15), 
breast (16) and bone (17). Therefore, these previous studies 
suggested that RAGE represents a potential therapeutic 
target, and that inhibiting RAGE may be useful to anticancer 
strategies.
Previously, Sakai et al (18) developed a novel drug design 
system, involving the conversion of optimized binding peptide 
to non-peptidic small molecules by structure-based virtual 
screening (SBVS), followed by optimization of the small 
molecules using a structure-based drug design system, namely 
conversion to small molecules through optimized-peptide 
strategy (COSMOS). Using this strategy, the most optimized 
binding peptide is first computationally designed on a hot spot 
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in the target protein. Subsequently, the optimized binding 
peptide may be converted to small molecules by SBVS 
based on its pharmacophore. Then, the selected candidates 
are evaluated using in vitro assays. Therefore, this strategy 
decreases the cost and time required to search for effective 
lead compounds, for drug design and for optimization (18). 
The present study identified a RAGE inhibitor, papaverine, 
using this drug design system. Papaverine is an opiate alka-
loid, originally isolated from the plant Papaver somniferum 
and now synthetically produced as a direct-acting smooth 
muscle relaxant. Its mechanism of action may be associated 
with non-selective inhibition of phosphodiesterases and direct 
inhibition of calcium channels (19,20).
The present study assessed whether papaverine functioned 
as a RAGE inhibitor using in vitro cell culture systems of 
RAGE- and dominant-negative (dn)RAGE-expressing HT1080 
fibrosarcoma cells.
Materials and methods
Papaverine. Papaverine hydrochloride (molecular weight, 
375.85 Da; product number, P0016) was purchased from 
Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan).
Cell lines. HT1080 human fibrosarcoma cells (American Type 
Culture Collection, Manassas, VA, USA) were transfected 
with a plasmid containing human full-length RAGE cDNA 
or cytoplasmic domain-deleted dnRAGE cDNA, or with the 
vector alone, as previously described (21,22). The cells were 
designated as RAGE-expressing, dnRAGE-expressing or 
mock-transfected (mock) HT1080 cells, respectively. Cells 
were maintained in RPMI-1640 medium (Nakarai Tesque, 
Kyoto, Japan) supplemented with 10% fetal bovine serum 
(FBS; Nichirei Biosciences Inc., Tokyo, Japan), 100 U/ml 
penicillin and 100 µg/ml streptomycin in the presence of G418 
(geneticin, 200 µg/ml; Roche Applied Science, Mannheim, 
Germany).
NF‑κB luciferase assay. Stably transfected rat C6 glioma cells 
that expressed human RAGE and the NF-κB enhancer-luciferase 
system (pNF-κB-Luc; Agilent Technologies, Inc., Santa 
Clara, CA, USA) were used in this assay, as previously 
described (21). After a 4 h incubation at 37˚C in a humidified 
5% CO2 atmosphere in Dulbecco's modified Eagle's medium 
supplemented with 0.1% FBS, the cells were stimulated with 
1 µg/ml HMGB-1 (Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany) or with 100 µg/ml glyceraldehyde-derived 
AGE‑modified bovine serum albumin (BSA) (Sigma‑Aldrich; 
Merck KGaA) (21) with/without 10 or 20 µM papaverine or 
0.08% dimethy sulfoxide (DMSO) as a negative control for 
4 h at 37˚C in a humidified 5% CO2 atmosphere. Luciferase 
activity was determined using the luciferase assay system 
(Promega Corporation, Madison, WI, USA) and an LB 941 
Multimode Reader TriStar (Berthold Technologies GmbH & 
Co. KG, Bad Wildbad, Germany). These experiments were 
repeated three times.
Western blot analysis. RAGE- and dnRAGE-expressing 
HT1080 cells and mock control cells which were incubated 
with 0, 10 and 20 µM papaverine for 72 h at 37˚C in a 
humidified 5% CO2 atmosphere, were washed with ice cold 
PBS, scraped off in PBS and pelleted by centrifugation at 
300 x g for 5 min at 4˚C. The cells were lysed immediately by 
sonication in 1% Triton X-100 (Sigma-Aldrich; Merck KGaA), 
50 mM Tris-HCl, pH 7.5, 150 mM NaCl and protease inhibitor 
cocktail (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 
and then centrifuged at 10,000 x g for 10 min at 4˚C. The cell 
lysates (50 µg of protein) were separated via 12.5% SDS-PAGE 
and electroblotted onto polyvinylidene fluoride membranes 
(EMD Millipore, Billerica, MA, USA). The membranes were 
blocked at room temperature for 1 h with 5% (w/v) non-fat 
dried milk in PBS, and then incubated at room temperature for 
1 h with either a rabbit anti‑human RAGE‑specific polyclonal 
antibody (1:1,000) produced as described previously (21) 
or a mouse anti β-actin antibody (cat. no. A5441, 1:10,000; 
Sigma-Aldrich; Merck KGaA). Goat anti-rabbit IRDye 680 
(cat. no. P/N 926-32221) and goat anti-mouse IRDye 800CW 
(P/N 925-32210) were diluted 10,000-fold and used as the 
secondary antibodies. The antigen-antibody complex was 
visualized using the Odyssey Infrared Imaging System version 
3.0 (LI-COR Biosciences, Lincoln, NE, USA). These experi-
ments were repeated two times. Secondary antibody only was 
used as a negative control.
Plate‑binding assays. Competitive binding inhibition 
assay with papaverine was performed using a 96-well 
AGE‑BSA‑coated plate as previously described (21). Briefly, 
50 ng/ml soluble RAGE (sRAGE) was incubated with or 
without 10 or 20 µM of papaverine or 0.08% DMSO as a nega-
tive control on an AGE-BSA-coated plate at room temperature 
for 1 h. Following incubation and washed three times with 
0.01% Tween-20, 0.15 M NaCl, 20 mM Tris-HCl (pH 7.5), 
horseradish peroxidase (HRP)-labeled anti-RAGE antibody 
(in human esRAGE ELISA kit; ready-to-use; cat. no. K1009-1; 
B-Bridge International, Inc., Santa Clara, CA, USA) was added 
and the plate was further incubated at room temperature for 
1 h. The HRP-labeled antibody-sRAGE-AGE complex was 
then detected by measuring the absorbance at 450 nm using 
the microplate reader iMark (Bio-Rad Laboratories, Inc., 
Hercules, CA, USA). These experiments were repeated three 
times.
Cell proliferation assay. RAGE- and dnRAGE-expressing 
HT1080 cells and mock control cells were inoculated 
(1x103 cells/well) at 37˚C in a humidified 5% CO2 atmosphere 
in a 96-well plate (BD Biosciences, Franklin Lakes, NJ, USA) 
containing RPMI-1640 medium supplemented with 10% FBS 
and 0, 10 or 20 µM papaverine or 0.08% DMSO as a negative 
control. Following inoculation, the total viable cell number 
was counted using a hemocytometer using the dye exclusion 
method with 0.2% Trypan blue at room temperature (Thermo 
Fisher Scientific, Inc.) using an inverted light microscope 
(Primovert, Zeiss, Carl Zeiss Industrielle Messtechnik GmbH, 
Oberkochen, Germany) at magnification, x4 objective at 0, 24, 
48 and 72 h. These experiments were repeated three times.
Cell migration assay. Cell migration was evaluated using 
the monolayer denudation assay as previously described (10). 
Briefly, RAGE‑ and dnRAGE‑expressing HT1080 and mock 
control cells were inoculated (2x105 cells/well) and were 
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cultured to 100% confluence in a 12‑well plate. Cells were 
then wounded by denuding a strip of the monolayer (width, 
~1 mm) with a 200 µl pipette tip. Cells were washed twice with 
serum-free RPMI-1640 medium, and then incubated for 20 h 
at 37˚C under a humidified 5% CO2 atmosphere in RPMI-1640 
containing 0.1% FBS with/without 10 or 20 µM papaverine or 
0.08% DMSO as negative control. The rate of wound closure 
was assessed in four separate fields of view 20 h after denuda-
tion using a light microscope (magnification, x4 objective). 
These experiments were repeated three times.
Cell invasion assay. A total of mg/ml of matrigel-coated porous 
filters (pore size, 8 µm) in a 24‑well format (BD Biosciences) 
were used as barriers in Boyden chambers to assess the extent 
of invasion by RAGE- and dnRAGE-expressing HT1080 cells 
and mock controls. Cells were plated (2x105 cells) in the upper 
chambers with RPMI-1640 containing 0.1% BSA in the pres-
ence or absence of 10 or 20 µM papaverine or 0.08% DMSO as 
negative control. The lower chambers were filled with 750 µl 
RPMI-1640 containing 1% FBS in the presence or absence of 
10 or 20 µM papaverine. Following a 20‑h incubation at 37˚C 
in a humidified 5% CO2 atmosphere, membranes were cut 
and removed from the insert housings. The filter membrane 
was fixed in 4% paraformaldehyde at room temperature for 
2 min following the removal of non-invasive cells from the 
upper surface using a cotton swab. The bottom surface with 
the invasive cells was stained with 0.1% crystal violet at room 
temperature for 1 min, and the invasive cells were counted 
in six fields of view using a light microscope (magnification, 
x4 objective) as previously described (10). These experiments 
were repeated three times.
Statistical analysis. Statistical analysis was performed using 
one-way analysis of variance with the Tukey-Kramer post-hoc 
test. These tests were conducted using Ekuseru-Toukei 2015 
(Social Survey Research Information Co., Ltd., Tokyo, Japan). 
Data are presented as mean ± standard error of the mean. 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Inhibitory effects of papaverine on RAGE‑dependent NF‑κB 
activity. The present study assessed the inhibitory effects of 
papaverine on the RAGE-dependent NF-κB intracellular 
signaling pathway. Using the C6 glioma system, which reflected 
RAGE-dependent NF-κB activity (21), HMGB-1-induced acti-
vation of NF-κB was evaluated in the presence or absence of 
papaverine in the culture media. Adding HMGB‑1 significantly 
induced intracellular NF-κB activation (P<0.01); however, this 
upregulation was inhibited by papaverine treatment (10 or 
20 µM; Fig. 1A). In addition, the increase in NF-κB activity 
induced by glyceraldehyde-derived AGE-BSA, another RAGE 
ligand, was significantly inhibited by papaverine (Fig. 1B). 
The results of the present study suggested that papaverine 
could inhibit the RAGE-dependent intracellular signaling 
pathway. The present study subsequently confirmed the 
papaverine-RAGE binding using a plate assay (21). Papaverine 
significantly and dose‑dependently competed for the binding 
between glyceraldehyde-derived AGE-BSA and recombinant 
soluble RAGE (Fig. 1C), which suggested that the binding site 
of papaverine to RAGE may be shared with that of AGE-BSA.
Figure 1. Papaverine inhibits HMGB-1 and AGE-BSA-induced RAGE 
signaling. Cells were stimulated with (A) 1 µg/ml HMGB-1 or (B) 100 µg/ml 
AGE-BSA with or without 10 or 20 µM papaverine for 4 h. The luciferase 
activity was measured and expressed as arbitrary units (AU). Values represent 
the mean ± standard error of the mean (n=3). BSA, 100 µg/ml non-glycated 
BSA as a negative control; **P<0.01 vs. 1 µg/ml HMGB-1; *P<0.05 vs. 1 µg/ml 
HMGB-1. (C) A plate binding assay. AGE-BSA-RAGE binding was competi-
tively inhibited by papaverine. **P<0.01 vs. 50 ng/ml soluble RAGE. HMGB, 
high mobility group box; AGE, advanced glycation end-products; BSA, 
bovine serum albumin; RAGE, receptor for advanced glycation end-products; 
OD, optical density; soluble RAGE, recombinant soluble RAGE.
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Inhibitory effects of papaverine on RAGE‑dependent cell prolif‑
eration, migration and invasion. To mimic RAGE-dependent 
tumor malignant behaviors and assess the inhibitory effects of 
papaverine, the present study used an established human fibro-
sarcoma cell line HT1080 that expressed human RAGE and 
dnRAGE and the mock control cells. The HT1080 cells expressed 
HMGB1 and secreted HMGB1 levels did not differ among the 
mock-transfected, RAGE-expressing and dnRAGE-expressing 
HT1080 cells (10). The present study assessed the effects of 
papaverine treatment on HT1080 cell proliferation. Papaverine 
significantly and dose‑dependently decreased the proliferation 
rate of RAGE-expressing HT1080 cells (P<0.05 vs. non-treated 
HT1080 cells; P<0.01 vs. non-treated HT1080 cells). In particular, 
at 20 µM it was most effective between treated and non-treated 
conditions in RAGE-expressing HT1080 cells (65.5% reduc-
tion) at 48 h (Fig. 2A). A reduction (39.8%) was also observed 
between treated and non-treated conditions in the mock control 
cells at 48 h; however, its effectiveness was decreased in 
dnRAGE-expressing HT1080 cells (26.2% reduction) (Fig. 2A). 
Papaverine did not change the protein expression levels of RAGE 
and dnRAGE in the RAGE-expressing and dnRAGE-expressing 
HT1080 cells, respectively (Fig. 2B). Whether papaverine 
could inhibit the RAGE-dependent migration and invasion 
of HT1080 cells was also assessed in vitro. The inhibitory 
effects of papaverine on cell migration were observed between 
treated and non-treated RAGE-expressing HT1080 cells. 
Additionally, the inhibitory effects were observed between 
treated and non-treated conditions in mock control cells (Fig. 3). 
However, no inhibitory effects of papaverine on migration were 
observed in dnRAGE-expressing HT1080 cells (Fig. 3), which 
indicated a selective inhibitory action of papaverine against 
RAGE. Furthermore, papaverine treatment significantly and 
dose-dependently inhibited HT1080 cell invasion in the Matrigel 
assay (P<0.01; Fig. 4). A statistically significant inhibitory effect 
of papaverine treatment was also identified between treated and 
non-treated dnRAGE-expressing HT1080 cells (P<0.01). The 
results of the present study demonstrated that papaverine may 
inhibit RAGE-dependent and RAGE-independent malignant 
phenotypes of cancer cells; the latter may include an antitumor 
effect of papaverine via an elevation of intracellular cyclic AMP 
by phosphodiesterase inhibition (8).
Discussion
RAGE is a multi-ligand, pattern recognition receptor that has 
been implicated in the growth, progression and metastasis of 
Figure 2. Papaverine decreases RAGE‑induced cell proliferation in HT1080 fibrosarcoma cells. (A) Total viable cell number was determined at 0, 24, 48 and 
72 h following inoculation of HT1080 RAGE, HT1080 dnRAGE and HT1080 mock cells in RPMI-1640 medium supplemented with 10% fetal bovine serum 
with or without 10 or 20 µM papaverine. Values represent the mean ± standard error of the mean (n=3). Open circle, non-treated control; closed triangle, 10 µM 
papaverine; closed square, 20 µM papaverine. *P<0.05 and **P<0.01 vs. non-treated control. (B) Western blotting. Human RAGE- and dnRAGE-expressing 
HT1080 and mock control cells were treated with or without papaverine for 72 h. Closed and open arrow heads indicate RAGE and dnRAGE proteins, 
respectively. RAGE, receptor for advanced glycation end-products; dn, dominant-negative.
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multiple types of human cancer (23,24). RAGE ligands include 
S100/calgranulins (S100A4, S100A6, S100A7, S100A8/9, 
S100A14, S100B and S100P) (2,25-29) and HMGB-1 protein, 
which have been demonstrated to be upregulated in glioma, 
melanoma, bladder, liver, pancreatic, prostate, colorectal, 
gastric and lung cancer (30-34). Ligand-RAGE signaling path-
ways enhance the properties associated with malignant tumor 
phenotypes (10,22,35-37), including by activating members 
of the small GTPase family (Cdc42 and Rac1), members of 
the mitogen-activated protein kinase family (extracellular 
signal-regulated kinase, p38 and stress-activated protein 
kinases/c-Jun amino-terminal kinases), NF-κB and the formin 
homology 1 domain (10,22,35-37). Therefore, blocking RAGE 
and ligand-RAGE signaling could represent a potential strategy 
Figure 3. Papaverine inhibits RAGE‑induced migration of HT1080 fibrosarcoma cells. (A) Scratch wound assay was performed using HT1080 RAGE, HT1080 
dnRAGE and HT1080 mock fibrosarcoma cells in 0.1% serum medium. (B) The filled wound area was measured. The black line represents the wound edge. 
-, non-treated control; 10, 10 µM papaverine; 20, 20 µM papaverine. Values represent the mean ± standard error of the mean (n=3). **P<0.01 between the two 
groups. RAGE, receptor for advanced glycation end-products; dn, dominant-negative.
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for treating certain types of cancer. Previous experimental studies 
have revealed that inhibiting RAGE suppressed tumor growth, 
invasion and angiogenesis in multiple types of cancer (10,16,38). 
The therapeutic efficacy of blocking RAGE from interacting 
with HMGB-1 was initially demonstrated in glioma cells, in 
which this blockade inhibited tumor growth and invasion (16). 
Subsequently, strategies and components of RAGE inhibition 
have been reported in oncology and other fields, including 
neurology (39,40). For example, RAGE-neutralizing antibodies 
and sRAGE decreased the emergence of lung metastasis 
following intracardiac injection of Lewis lung carcinoma 
cells (39,40). In addition, endogenous secretory receptor for 
advanced glycation end products, another soluble decoy form of 
RAGE, was demonstrated to inhibit Aβ-42 uptake into mouse 
brain; therefore, it may be effective in AD (41). Hong et al (42) 
evaluated the effects of the RAGE‑specific inhibitor FPS‑ZM1 
on Aβ metabolism, AGE‑induced inflammation and oxidative 
stress in rat hippocampus. In addition, blocking RAGE signaling 
in tumor-associated macrophages has been proposed as a 
potential anticancer strategy; the macrophages form the tumor 
Figure 4. Papaverine inhibits RAGE‑induced invasion of HT1080 fibrosarcoma cells. (A) Matrigel cell invasion assay was performed using HT1080 RAGE, 
HT1080 dnRAGE and HT1080 mock fibrosarcoma cells. Scale bar, 1 mm. (B) The number of migrating cells was determined. ‑, non‑treated control; 10, 
10 µM papaverine; 20, 20 µM papaverine. Values represent the mean ± standard error of the mean (n=3). **P<0.01. RAGE, receptor for advanced glycation 
end-products; dn, dominant-negative.
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microenvironment, which could drive tumor angiogenesis (30). 
FPS-ZM1 directly inhibited primary tumor growth; in addition, 
it blocked RAGE signaling in tumor-associated macrophages, 
inhibited tumor angiogenesis and inflammatory cell recruit-
ment and inhibited metastasis to the lungs and liver (16). 
Another RAGE-binding peptide, RP-1, was demonstrated to 
inhibit Aβ-induced cellular stress in human neuroblastoma 
cells in vitro (43). Furthermore, Han et al (44) reported that 
4,6-bisphenyl-2-(3-alkoxyanilino) pyrimidine inhibited the 
binding of Aβ to RAGE.
The present study identified papaverine as a RAGE inhibitor 
using the drug design system COSMOS, an example of drug 
repositioning, the application of well-known existing drugs 
and compounds for novel indications. As a structure from 
which researchers could develop novel drugs, papaverine could 
represent a potential precursor to a therapeutic RAGE inhibitor. 
RAGE has been implicated in multiple pathogenic processes, in 
cancer and numerous other diseases, including diabetes, athero-
sclerosis, inflammatory and neurodegenerative diseases (7‑9,45). 
Therefore, papaverine and its derivatives could be useful in 
preventing and treating multiple RAGE-associated diseases. To 
clarify our understanding of RAGE inhibition by papaverine, 
in vivo animal models should be used in future studies.
To conclude, the results of the present study suggested 
papaverine could inhibit RAGE and provided novel insights 
into the field of RAGE biology.
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